Hosted on MSN2mon
Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here's what the science saysThe craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better known under the trade names Ozempic and Wegovy, is remarkable ...
News Medical on MSN1d
Expert explores the expanding applications of GLP1 therapiesSemaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...
Hosted on MSN15d
Amgen speaks out about bone density concerns with obesity drugAmgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
The company announced the positive data for the dual glucagon-like peptide-1 receptor (GLP-1R)/gastric inhibitory polypeptide (GIP) receptor agonist at ObesityWeek 2024, taking place in Texas ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
OBJECTIVE Gastric bypass (GB ... Plasma levels of the incretin glucagon-like peptide 1 (GLP-1) are dramatically increased after GB, suggesting that its action contributes to alteration in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback